24СʱÈÈÃŰæ¿éÅÅÐаñ    

²é¿´: 1254  |  »Ø¸´: 5
±¾Ìû²úÉú 1 ¸ö ·­ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

polarmouse

Ìú³æ (³õÈëÎÄ̳)

[ÇóÖú] ÇóÁ½¶Î·­Ò룬·Ç³£½ô¼±£¬¸Ð¼¤ÌéÁã

In open-label, randomized, three-period, three-treatment crossover studies, 10 subjects received 10 mg A, 45 mg B or the combination, while20 subjects received 20 mg A, 1000 mg C or the combination. In an open-label, randomized, five-period, five-treatment, unbalanced crossover study, 12 subjects first received 20 mg A, 4 mg D or the combination, and afterward 100 mg sitagliptin or sitagliptin plus 20 mg A. Blood samples were taken over 72 h of each treatmentperiod. Lack of PK interaction was defined as the ratio of geometric means and 90% confidence interval (CI) for combination:monotherapy being within the range of 0.80¨C1.25 ¡£
   Co-administration of A withB, C or D had no effect on A maximum plasma concentration (Cmax) or area under the plasma concentration-time curve (AUC). Similarly, A did not affect the Cmax or AUC for the co-administered drug, except for slight extensions of the 90% CI for the ratio of geometric means for B AUC (upper limit 1.29) andC Cmax (lower limit 0.75). All monotherapies and combination therapies were well tolerated.
    A can be co-administered with B¡¢C¡¢Dwithout dose adjustment of either drug

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

Mally89

Ìú¸Ëľ³æ (Ö°Òµ×÷¼Ò)

T_T

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
sltmac(½ð±Ò+41, ·­ÒëEPI+1): 2011-05-16 07:52:15
sltmac: ¼ÌÐøÅ¬Á¦~~ 2011-05-16 07:52:30
In open-label, randomized, three-period, three-treatment crossover studies, 10 subjects received 10 mg A, 45 mg B or the combination, while20 subjects received 20 mg A, 1000 mg C or the combination. In an open-label, randomized, five-period, five-treatment, unbalanced crossover study, 12 subjects first received 20 mg A, 4 mg D or the combination, and afterward 100 mg sitagliptin or sitagliptin plus 20 mg A¡£
ÔÚ½øÐгÖÐøÈý¸öÖÜÆÚ£¬Ëæ»ú¿ª·Å±ê¼ÇµÄÈý¸ö´¦Àí½»²æÖÎÁÆÑо¿µ±ÖУ¬10¸öÑù±¾ÖмÓÈë10mgµÄA£¬45mgµÄB»òÕß¶þÕߵĻìºÏÎÁíÍâ20¸öÑù±¾ÖмÓÈë20mgµÄA¡¢1000mgµÄC»òÕß¶þÕߵĻìºÏÎï¡£ÔÚÁíÒ»¸öËæ»ú¿ª·Å±ê¼Ç£¬Î¬³Ö5¸öÖÜÆÚµÄ5¸ö½»²æ²»Æ½ºâ´¦ÀíÑо¿µ±ÖУ¬Ê×ÏÈÏò12¸öÑù±¾ÖмÓÈë20mg A£¬4mg D»òÕß¶þÕß»ìºÏÎȻºóÔÙ¼ÓÈë100mgÎ÷ËûÁÐÍ¡»ò¼ÓÓÐ20mgAµÄÎ÷ËûÁÐÍ¡¡£
5Â¥2011-05-08 15:22:48
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 6 ¸ö»Ø´ð

Mally89

Ìú¸Ëľ³æ (Ö°Òµ×÷¼Ò)

T_T

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

Blood samples were taken over 72 h of each treatment period. Lack of PK interaction was defined as the ratio of geometric means and 90% confidence interval (CI) for combination:monotherapy being within the range of 0.80¨C1.25 ¡£
ÿ¸ö´¦ÀíÖÜÆÚ72Сʱ֮ºó½«ÑªÒºÑù±¾È¡³ö¡£¸ù¾Ý¼¸ºÎ·½·¨ºÍ»ìºÏÎï90%ÖÃÐÅÇø¼ä£¨ÔÚ0.8-1.25·¶Î§Äڵĵ¥Ò»ÖÎÁÆ£©µÄ±ÈÖµÀ´Åж¨½»²æ·´Ó¦ÖÐÊÇ·ñȱ·¦PK¡£
6Â¥2011-05-08 16:09:08
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 280·ÖÇóµ÷¼Á Ò»Ö¾Ô¸085802 +4 PUMPT 2026-03-22 7/350 2026-03-22 22:13 by ÐÇ¿ÕÐÇÔÂ
[¿¼ÑÐ] 311Çóµ÷¼Á +6 ¶¬Ê®Èý 2026-03-18 6/300 2026-03-22 20:18 by edmund7
[¿¼ÑÐ] 323Çóµ÷¼Á +5 ÍÝСͰ 2026-03-18 5/250 2026-03-22 17:38 by luoyongfeng
[¿¼ÑÐ] Çóµ÷¼Á +6 Ê®Èý¼ÓÓÍ 2026-03-21 6/300 2026-03-22 17:00 by i_cooler
[¿¼ÑÐ] 280Çóµ÷¼Á +11 ¹¾ààÏþÏþ 2026-03-18 12/600 2026-03-21 22:40 by ACS Nano¡ª¡ª
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤£¨0856£©304ÇóBÇøµ÷¼Á +3 Çñgl 2026-03-20 7/350 2026-03-21 19:05 by 15709483992
[¿¼ÑÐ] Ò»Ö¾Ô¸ÖйúʯÓÍ´óѧ£¨»ª¶«£© ±¾¿ÆÆë³¹¤Òµ´óѧ +3 ʯÄÜΰ 2026-03-17 3/150 2026-03-21 02:22 by JourneyLucky
[¿¼ÑÐ] 265Çóµ÷¼Á +9 ÁºÁºÐ£Ð£ 2026-03-17 9/450 2026-03-21 02:17 by JourneyLucky
[¿¼ÑÐ] Ò»Ö¾Ô¸»ªÄÏʦ´ó 070300£¨»¯Ñ§£©304·ÖÇóµ÷¼Á +3 0703ÎäÜ·»ÛÑ©304 2026-03-18 3/150 2026-03-21 00:48 by JourneyLucky
[¿¼ÑÐ] 304Çóµ÷¼Á +6 ÂüÊâ2266 2026-03-18 6/300 2026-03-21 00:32 by JourneyLucky
[¿¼ÑÐ] Ò»Ö¾Ô¸Äϲý´óѧ£¬327·Ö£¬²ÄÁÏÓ뻯¹¤085600 +9 Ncdx123456 2026-03-19 9/450 2026-03-20 23:41 by lovewei0727
[¿¼ÑÐ] Ò»Ö¾Ô¸Öк£Ñó²ÄÁϹ¤³Ìר˶330·ÖÇóµ÷¼Á +8 С²Ä»¯±¾¿Æ 2026-03-18 8/400 2026-03-20 23:16 by JourneyLucky
[¿¼ÑÐ] Ò»Ö¾Ô¸ Î÷±±´óѧ £¬070300»¯Ñ§Ñ§Ë¶£¬×Ü·Ö287£¬Ë«·ÇÒ»±¾£¬Çóµ÷¼Á¡£ +4 ³¿»èÏßÓëÐǺ£ 2026-03-19 4/200 2026-03-20 22:15 by JourneyLucky
[¿¼ÑÐ] Ò»Ö¾Ô¸ËÕÖÝ´óѧ²ÄÁÏÇóµ÷¼Á£¬×Ü·Ö315£¨Ó¢Ò»£© +5 sbdksD 2026-03-19 5/250 2026-03-20 22:10 by luoyongfeng
[¿¼ÑÐ] 329Çóµ÷¼Á +9 ÏëÉÏѧ߹߹ 2026-03-19 9/450 2026-03-20 22:01 by luoyongfeng
[¿¼ÑÐ] Ò»Ö¾Ô¸¼ªÁÖ´óѧ²ÄÁÏѧ˶321Çóµ÷¼Á +11 Ymlll 2026-03-18 15/750 2026-03-20 19:40 by ¶¡¶¡*
[¿¼ÑÐ] ¹¤¿Æ²ÄÁÏ085601 279Çóµ÷¼Á +7 À§ÓÚÐdz¿ 2026-03-17 9/450 2026-03-20 17:38 by ÎÞи¿É»÷111
[¿¼ÑÐ] 281Çóµ÷¼Á£¨0805£© +14 ÑÌÏ«Ò亣 2026-03-16 25/1250 2026-03-20 15:47 by yuncha
[¿¼ÑÐ] 334Çóµ÷¼Á +3 Ö¾´æ¸ßÔ¶ÒâÔÚ»úÐ 2026-03-16 3/150 2026-03-18 08:34 by lm4875102
[¿¼ÑÐ] 275Çóµ÷¼Á +4 Ì«Ñô»¨ÌìÌ쿪ÐÄ 2026-03-16 4/200 2026-03-17 10:53 by ¹¦·ò·è¿ñ
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û